2-(5'-ethyl-3,6-dihydro-2H-[1,2'-bipyridin]-4-yl)-4-((4-(methylsulfonyl)phenoxy)methyl)thiazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(5'-ethyl-3,6-dihydro-2H-[1,2'-bipyridin]-4-yl)-4-((4-(methylsulfonyl)phenoxy)methyl)thiazole
• 英文别名: 2-[1-(5-ethylpyridin-2-yl)-3,6-dihydro-2H-pyridin-4-yl]-4-[(4-methylsulfonylphenoxy)methyl]-1,3-thiazole
• 化学式: C₂₃H₂₅N₃O₃S₂
• 分子量: 455.602
• InChiKey: KIRNINKYOSCBMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.38
• 重原子数：
  31.0
• 可旋转键数：
  7.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.39
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为产物：
  描述：

  哌啶-4-甲酰胺 在 劳森试剂 、 四氯化碳 、 4-二甲氨基吡啶 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 magnesium sulfate 、 potassium carbonate 、 caesium carbonate 、 三氟乙酸 、 potassium iodide 、 magnesium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 为溶剂， 反应 6.0h， 生成 2-(5'-ethyl-3,6-dihydro-2H-[1,2'-bipyridin]-4-yl)-4-((4-(methylsulfonyl)phenoxy)methyl)thiazole
  参考文献：
  名称：

  Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists

  摘要：

  A series of novel tetrahydropyridine derivatives were prepared and evaluated using cell-based measurements. Systematic optimization of general structure G-1 led to the identification of compound 35 (EC50 = 4.9 nM) and 37 (EC50 = 8.8 nM) with high GPR119 agonism activity and moderate clog P. Through single and long-term pharmacodynamic experiments, we found that compound 35 showed a hypoglycemic effect and may have an effect on improving basal metabolic rate in DIO mice. Both in vitro and in vivo tests indicated that compound 35 was a potential potent GPR119 agonist in allusion to T2DM treatment.

  DOI：

  10.1016/j.bmcl.2019.126855

文献信息

• Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists
  作者：Zeping Zuo、Miaomiao Chen、Xiaoni Shao、Xinying Qian、Xiaocong Liu、Xia Zhou、Jiawei Xiang、Pengchi Deng、Yan Li、Hui Jie、Chunqi Liu、Xiaobo Cen、Yongmei Xie、Yinglan Zhao

  DOI：10.1016/j.bmcl.2019.126855

  日期：2020.2

  A series of novel tetrahydropyridine derivatives were prepared and evaluated using cell-based measurements. Systematic optimization of general structure G-1 led to the identification of compound 35 (EC50 = 4.9 nM) and 37 (EC50 = 8.8 nM) with high GPR119 agonism activity and moderate clog P. Through single and long-term pharmacodynamic experiments, we found that compound 35 showed a hypoglycemic effect and may have an effect on improving basal metabolic rate in DIO mice. Both in vitro and in vivo tests indicated that compound 35 was a potential potent GPR119 agonist in allusion to T2DM treatment.